USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19 (IVERCAR)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04425850|
Recruitment Status : Active, not recruiting
First Posted : June 11, 2020
Last Update Posted : June 17, 2020
Estimation of the prevalence and contagiousness of undocumented novel coronavirus infections is critical for understanding the overall prevalence and pandemic potential of this disease.
It is estimated that 86% of all infections were undocumented [95% credible interval (CI): 82-90%] before the 23 January 2020 travel restrictions. The transmission rate of undocumented infections per person was 55% the transmission rate of documented infections (95% CI: 46-62%), yet, because of their greater numbers, undocumented infections were the source of 79% of the documented cases.
Ivermectin + Carrageenan, taking advantage of their virucidal effects, are aimed at reducing the contagion.
|Condition or disease||Intervention/treatment|
|Contagious Pleuropneumonia||Device: iota carrageenan Drug: Ivermectin|
|Study Type :||Observational|
|Estimated Enrollment :||70 participants|
|Official Title:||USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid Among Healthy People and Health Personnel|
|Actual Study Start Date :||June 1, 2020|
|Estimated Primary Completion Date :||August 30, 2020|
|Estimated Study Completion Date :||August 30, 2020|
Adults, both genders, no age limit. They will be provided with topical medication, to be used 5 times a day. PPEs used as suggested by OMS.
Device: iota carrageenan
topical use on nasal mucosae
Other Name: Nasitral
Topical use on oral mucosae
Other Name: Ivercass
Same as IVER+ They will follow PPEs suggestions, only.
- Reduction in contagion [ Time Frame: 30 days ]For Health Personnel, the average dessertion all over the world has raised to 27 % worldwide. We aim at reducing it dramaticaly.
- Secondary and or side effects [ Time Frame: 7 days ]Allergy to any of the two drugs administered topically
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04425850
|Buenos Aires, Argentina, 1802|